Dr. David S. Allan MD FRCP(C) is a scientist in the Regenerative Medicine Program at the Ottawa Hospital Research Institute (OHRI) and a hematologist with the Blood and Marrow Transplant Program at The Ottawa Hospital. He writes about the cord blood clinical trials on novel indications.
Some excerpts from the article:
In addition to blood-forming stem cells, umbilical cord blood contains other progenitor cells that may be useful in the treatment of organ injury or to dampen immune responses in a range of novel indications. To better understand the field of studies that have been performed for these novel indications, we performed a systematic scoping review of the literature and clinical trial registries through the end of 2012. We examined the PubMed, EMBASE and Cochranedatabases of publications, and trials registered with ClinicalTrials.gov or the WHO’s platform ICTRP.
We identified a total of 20 published studies using umbilical cord blood cells and 47 ongoing clinical trials that had not yet completed enrolment. The types of disorders that were being studied cover: neurological disorders including autism, cerebral palsy and spinal cord injury, cardiac and vascular disorders, liver disease and immune conditions such as diabetes.
The studies published through the end of 2012 contained 317 patients who had received umbilical cord blood transplants for novel indications. This limited numbr of patients were treated for a broad range of conditions. The cord blood stem cells came from both public and family cord blood banks, and the patients included both adults and children.
Read full article here: < a href=”http://parentsguidecordblood.org/newsletter_archive/newsletters_2014-07….